Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06599385
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-13
Brief Title:
Platelet Transfusion in Critically Ill Patients With Thrombocytopenia
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Platelet Transfusion in Critically Ill Patients With Thrombocytopenia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TRAMPOLINE
Brief Summary:
Thrombocytopenia is a common biological disorder in critically ill patients The main supportive treatment is platelet transfusion with the aim of preventing and treating bleeding and securing invasive procedures Current guidelines suggest that prophylactic platelet transfusion should probably be administered in non-bleeding critically ill patients at platelet count triggers of 10 to 20 GL albeit with very low certainty since extrapolated from studies carried out in stable patients with hematological malignancies Indications for prophylactic platelet transfusion have not been properly addressed in adult ICU patients with regard to their particular risk of bleeding and prognosis We propose the TRAMPOLINE study in order to address two different platelet count thresholds of 10 GL low threshold or 20 GL high threshold for the prevention of ICU-acquired bleeding in critically ill patients with severe thrombocytopenia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None